inborn errors of metabolism
Metabolic · 2018–2021
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| Amino acid formula with vitamins and minerals (multiple formulations) Dietary management of inborn errors of amino acid metabolism (homocystinuria, phenylketonuria, tyrosinaemia, and maple syrup urine disease) in patients from… | Jul 2021 | Recommended with restriction | unclear |
| triglycerides, long chain with glucose polymer Nutritional supplementation for patients with proven inborn errors of metabolism who are unable to meet their energy requirements with permitted food and… | Mar 2018 | Noted | no section in document |
What the PBS pays
$17M in government benefit over 2024–25, across 16,868 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amino acid formula with vitamins and minerals (multiple formulations) | $17M |
| triglycerides, long chain with glucose polymer | $0.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.